Syndicate content

Archive - Dec 18, 2019

  • All
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31

Three-Drug Combination Improves Lung Function in Most Common Genetic Form of Cystic Fibrosis

A phase three clinical trial that the University of Texas (UT) Southwestern Medical Center participated in has determined that a three-drug combination improved lung function and reduced symptoms in cystic fibrosis (CF) patients who have a single copy of the most common genetic mutation for the disease. Earlier this month, the Food and Drug Administration approved the therapy based on the results of this international study, published online on October 31, 2019 and in the November 7, 2019 issue of the New England Journal of Medicine. The article is titled “Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.” A companion investigation, appearing simultaneously in The Lancet, reported on people with one or two copies of the mutation. The Lancet article, published online on October 31, 2019 and in the November 23, 2019 issue, is titled “Efficacy and Safety of the Elexacaftor Plus Tezacaftor Plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial.” A commentary article (“Entering the Era of Highly Effective CFTR Modulator Therapy”) also appears in The Lancet. Raksha Jain (photo), MD, Associate Professor of Internal Medicine at UT Southwestern Medical Center, is corresponding author of the NEJM article and an investigator on The Lancet study. Dr. Jain presented both studies at the North American Cystic Fibrosis Conference 2019 in Nashville October 31 to November 2. CF is a chronic, progressive, and frequently fatal genetic disease that affects the respiratory and digestive systems in children and young adults. The sweat glands and the reproductive system are usually also involved. Individuals with CF have a shortened lifespan.

Study Reveals Domestic Horse Breed (Cleveland Bay) Has Third-Lowest Genetic Diversity, Just Higher Than Friesian & Clydesdale Breeds

A new study by Dr. Gus Cothran, Professor Emeritus at the Texas A&M School of Veterinary Medicine & Biomedical Sciences (CVM), has found that the Cleveland Bay (CB) horse breed has the third-lowest genetic variation level of domestic horses, ranking above only the notoriously inbred Friesian and Clydesdale breeds. This lack of genetic diversity puts the breed at risk for a variety of health conditions. Genetic variation refers to the differences between different individuals' DNA codes. Populations where there is high genetic diversity will have a wider range of different traits and will be more stable, in part because disease traits will be more diluted. In populations with low genetic variation, many individuals will have the same traits and will be more vulnerable to disease. The CB is the United Kingdom's oldest established horse breed and the only native warm-blood horse in the region. Used for recreational riding, driving, and equestrian competition, the CB is considered a critically endangered breed by the Livestock Conservancy. Because maintaining genetic diversity within the breed is important to securing the horses' future, Dr. Cothran and his team worked to gain comprehensive genetic information about the breed to develop more effective conservation and breeding strategies. In this study, published online on Septembr 20, 2019 in Diversity, researchers genotyped hair from 90 different CB horses and analyzed their data for certain genetic markers. These samples were then compared to each other, as well as to samples from other horse breeds to establish the genetic diversity within the breed and between other breeds.

MicroRNA-1 Alleviates Protein Accumulation by Controlling Autophagy; Finding May Be Key to New Therapeutic Approaches in Huntington’s Disease and Parkinson’s Disease

Research led by a Monash University (Australia) scientist has identified a highly conserved mechanism in worms and humans that controls the removal of toxic protein aggregates – hallmarks of neurodegenerative diseases. Insights from their study may provide a novel therapeutic approach for diseases such as Huntington's and Parkinson's. Associate Professor Roger Pocock, from the Monash Biomedicine Discovery Institute (BDI), and colleagues from the University of Cambridge led by Professor David Rubinsztein, found that microRNAs are important in controlling protein aggregates, proteins that have amassed due to a malfunction in the process of ‘folding’ that determines their shape. The scientists’ findings were published online on December 9, 2019 in eLIFE. The open-access article is titled “Interferon-β-Induced miR-1 Alleviates Toxic Protein Accumulation by Controlling Autophagy.” MicroRNAs, short strands of genetic material, are tiny but powerful molecules that regulate many different genes simultaneously. The scientists sought to identify particular microRNAs that are important for regulating protein aggregates and homed in on miR-1, which is found in low levels in patients with neurodegenerative diseases such as Parkinson’s disease. “The sequence of miR-1 is 100 per cent conserved; it’s the same sequence in the Caenorhabditis elegans worm as in humans even though they are separated by 600 million years of evolution,” Associate Professor Pocock said. “We deleted miR-1 in the worm and looked at the effect in a preclinical model of Huntington’s and found that when you don’t have this microRNA there’s more aggregation,” he said. “This suggested miR-1 was important to remove Huntington’s aggregates.”

Scientists Find Way to Supercharge Protein Production; Discovery Promises to Aid Production of Protein-Based Drugs, Vaccines, Other Biomaterials

Medicines such as insulin for diabetes and clotting factors for hemophilia are hard to synthesize in the lab. Such drugs are based on therapeutic proteins, so scientists have engineered bacteria into tiny protein-making factories. But even with the help of bacteria or other cells, the process of producing proteins for medical or commercial applications is laborious and costly. Now, researchers at the Washington University School of Medicine in St. Louis have discovered a way to supercharge protein production up to a thousand-fold. The findings, published online on December 18, 2019 in Nature Communications, could help increase production and drive down costs of making certain protein-based drugs, vaccines, and diagnostics, as well as proteins used in the food, agriculture, biomaterials, bioenergy, and chemical industries. The open-access article is titled “A Short Translational Ramp Determines the Efficiency of Protein Synthesis.” “The process of producing proteins for medical or commercial applications can be complex, expensive, and time-consuming,” said Sergej Djuranovic, PhD, an Associate Professor of Cell Biology and Physiology and the study’s senior author. “If you can make each bacterium produce 10 times as much protein, you only need one-tenth the volume of bacteria to get the job done, which would cut costs tremendously. This technique works with all kinds of proteins because it’s a basic feature of the universal protein-synthesizing machinery.” Proteins are built from chains of amino acids hundreds of links long. Dr. Djuranovic and first author Manasvi Verma, an undergraduate researcher in Dr. Djuranovic’s lab, stumbled on the importance of the first few amino acids when an experiment for a different study failed to work as expected.

Scientists Discover New Mechanism in Childhood Kidney Cancer (Wilms’ Tumor); Findings on Possible Role of ENL Chromatin Reader Protein May Point to New Treatment Approaches

As an embryo develops, its cells must learn what to do with the thousands of genes they've been equipped with. That's why each cell comes with a detailed gene-expression manual outlining exactly which genes should be switched on, to what extent, and when. To execute their respective manuals, the cells employ so-called chromatin reader proteins that identify which gene is up for expression. Now, a new study has found that a problem in this gene-regulatory process may cause normal cells to turn malignant and produce Wilms’ tumor, the most common kidney cancer in children. The findings, which were published online on December 18, 2019, in Nature, open up new treatment possibilities for the disease, which is currently treated by surgery and chemotherapy. The article is titled “Impaired Cell Fate Through Gain-of-Function Mutations in a Chromatin Reader.” The findings also raise intriguing questions about other cancer types. The researchers found that the implicated reader protein causes problems by acquiring a new property and being too active. "We have never seen this type of mechanism before," says Liling Wan, PhD, a former postdoctoral associate in the Rockefeller Univeersity lab of Dr. C. David Allis, and now an Assistant Professor at the University of Pennsylvania. "It raises the question whether this type of molecular mechanism is also hijacked in other cancer types." A few years ago, Dr. Wan discovered that a reader protein called ENL is involved in blood cancer leukemia by activating the cancer-causing genes. Her attention was turned to Wilms' tumor recently, when it was discovered that some people with Wilms' tumor carry mutations in the gene that codes for ENL.

Bio-Techne's Exosome Diagnostics Lab Receives Accreditation from College of American Pathologists (CAP); Recognition Builds on Recent Achievements of Company’s ExoDx™ Prostate (IntelliScore) (EPI) Exosome-Based Liquid Biopsy Test

In a December17, 2019 press release, Bio-Techne Corporation (NASDAQ:TECH) announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a recent on-site inspection as part of the CAP's Accreditation Program. ExosomeDx was advised of this national recognition and congratulated for the excellence of services being provided. ExosomeDx is now one of more than 8,000 CAP-accredited facilities worldwide. "Receipt of CAP Accreditation represents another milestone in a banner year for our ExosomeDx platform and team," commented Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "This accreditation, combined with the CLIA, ISO 13485 and New York certifications already awarded to our laboratory, serve as a testament to the high-quality standards at our Waltham, Massachusetts facility. This recognition builds on the recent achievements of our ExoDx™ Prostate (IntelliScore) (EPI) test, including NCCN guideline inclusion, attaining FDA Breakthrough Device Designation, as well as the recently effective Medicare reimbursement determination issued by Medicare Administrative Contractor (MAC) National Government Services, Inc. All of these achievements position Bio-Techne to scale our EPI test and enable men to make more informed decisions on whether to proceed with an initial prostate biopsy.” Johan Skog (, PhD, CSO of Exosome Diagnostics, willbe giving a presentation at the upcoming Precision Medicine World Conference (PMWC 2020) in Santa Clara, California (January 21-January 24) (